Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:conditionStudied |
metastatic castration-resistant prostate cancer
|
| gptkbp:controlArm |
standard care
|
| gptkbp:eligibility |
PSMA-positive metastatic castration-resistant prostate cancer
|
| gptkbp:endPoint |
overall survival
radiographic progression-free survival |
| gptkbp:enrollment |
831
|
| gptkbp:experimentalArm |
177Lu-PSMA-617 plus standard care
|
| gptkbp:fullName |
VISION: A Study of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer
|
| https://www.w3.org/2000/01/rdf-schema#label |
VISION trial
|
| gptkbp:location |
international
|
| gptkbp:number |
NCT03511664
|
| gptkbp:period |
Phase 3
|
| gptkbp:publicationYear |
2021
|
| gptkbp:publishedIn |
gptkb:New_England_Journal_of_Medicine
|
| gptkbp:result |
improved overall survival
improved radiographic progression-free survival |
| gptkbp:sponsor |
gptkb:Novartis
|
| gptkbp:startYear |
2018
|
| gptkbp:studiedDrug |
177Lu-PSMA-617
|
| gptkbp:yearCompleted |
2021
|
| gptkbp:bfsParent |
gptkb:Pluvicto
|
| gptkbp:bfsLayer |
6
|